| Budget Amount *help |
¥16,900,000 (Direct Cost: ¥13,000,000、Indirect Cost: ¥3,900,000)
Fiscal Year 2019: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2018: ¥6,890,000 (Direct Cost: ¥5,300,000、Indirect Cost: ¥1,590,000)
Fiscal Year 2017: ¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000)
|
|---|
| Outline of Final Research Achievements |
We have previously found that the anti-malaria agent amodiaquine is active against the replication of severe fever with thrombocytopenia syndrome virus (SFTSV). When the anti-SFTSV activity of 100 amodiaquine derivatives was examined, a novel derivative (# 90) was identified as a potent and selective inhibitor of SFTSV in vitro. Its antiviral activity was approximately 10-fold higher than that of amodiaquine. When its mechanism of action was studied, # 90 was appeared to act on a rather early event in the viral replication cycle and exert its anti-SFTSV activity. When # 90 and favipiravir was combined, it exhibited an additive antiviral effect. The results of mouse experiments revealed that # 90 had a problem of its pharmacokinetics, suggesting that its formulation change or chemical modification will be required.
|
